Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × Infusions, Parenteral × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 58 Cyclophosphamide 52 Carboplatin 51 Paclitaxel 43 Nivolumab 40 Cisplatin 39 Gemcitabine 36 Dexamethasone 34 Radiotherapy 30 Capecitabine 28 Rituximab 25 Docetaxel 25 fludarabine 24 Bevacizumab 24 venetoclax 21 avelumab 21 Cytarabine 20 atezolizumab 19 Trastuzumab 19 Oxaliplatin 19 Fluorouracil 19 Cetuximab 19 130-nm albumin-bound paclitaxel 19 fludarabine phosphate 18 Temozolomide 18 Pemetrexed 18 Lenalidomide 18 Bortezomib 18 Azacitidine 18 Albumin-Bound Paclitaxel 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00889733 2024-03-26

OVHM-01

University Health Network, Toronto

Phase 1/2 Terminated

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡